Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  fluorouracil injection
Find trials that include:  Any drugs shown
Results 1-25 of 99 for your search:
Start Over
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1048, NCI-2012-00234, CDR0000715321, NCCTG-N1048, PN1048_A11PAMDREVW01, NCT01515787
Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-HN001, NCI-2014-00635, NCT02179164, RTOG-1305, NCT02135042
Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, NCT02265692, NCT00980460
Combination Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Locally Advanced Pancreatic Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: PANC0015, NCI-2013-01658, 5136, NCT01926197
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: EP-GF-301, NCI-2013-02181, NCT01954992
Imiquimod, Fluorouracil, or Observation in Treating Patients With High-Grade Anal Squamous Skin Lesions Who Are HIV-Positive
Status: Active
Phase: Phase III
Type: Treatment
Age: 27 and over
Trial IDs: AMC-088, NCI-2013-02288, NCT02059499
Topical or Ablative Treatment in Preventing Anal Cancer in Patients with HIV and Anal High-Grade Squamous Intraepithelial Lesions
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Age: 35 and over
Trial IDs: AMC-A01, NCI-2014-00636, NCT02135419
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-062, NCI-2015-01332, 163187, 2015-000972-88, NCT02494583
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D419LC00001, NCI-2015-02221, NCT02551159
GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-296-1080, NCI-2016-00148, 2015-001526-42, NCT02545504
Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100)
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: EMR 100070-007, NCI-2016-00646, 2015-003300-23, NCT02625610
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
Veliparib and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-608, NCI-2013-00656, NCT01489865
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
S1313, Combination Chemotherapy with or without PEGPH20 in Treating Patients with Newly Diagnosed Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1313, NCI-2013-01776, PS1313_A09PAMDREVW01, NCT01959139
Pembrolizumab, Combination Chemotherapy, and Celecoxib in Treating Patients with Advanced Colorectal, Appendix, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: PaTK02, NCI-2015-00859, NCT02446093
Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: ABI-007-PANC-009, NCI-2016-00214, NCT02620800
Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients with Untreated Metastatic Pancreatic Cancer
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 265214, NCI-2015-01597, NCT02575508
Bispecific Antibody Armed Activated T-cells with Aldesleukin and Sargramostim in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-100, NCI-2015-01942, 1510014428, NCT02620865
Start Over